Precision BioSciences, Inc. has made significant strides in its clinical research, as detailed in a recent SEC filing. The company announced advancements in its PBGENE-HBV program for chronic hepatitis B and the FUNCTION-DMD trial for Duchenne muscular dystrophy (DMD). These developments are crucial for the company as they enhance its product pipeline and potential market position.

About Precision BioSciences

Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, specializing in biological products, specifically gene editing therapies. The company is publicly traded on the Nasdaq under the ticker symbol DTIL. It operates as a smaller reporting company and has a focus on developing innovative treatments for chronic diseases.

What the Filing Says

According to the SEC filing dated November 5, 2026, Precision BioSciences provided updates on its clinical trials. The company reported that the PBGENE-HBV program has successfully advanced to Phase 2, with key findings indicating that the therapy achieved its target profile at a 0.4 mg/kg dose. The filing noted, "Phase 1 ELIMINATE-B study successful, PBGENE-HBV program advancing to Phase 2." Additionally, the first patient dosed with PBGENE-DMD completed the eight-week observation period with no reported safety concerns.

Impact

These advancements could significantly affect patients suffering from chronic hepatitis B and DMD, as they signal progress in developing effective treatments. The successful Phase 1 results for PBGENE-HBV and the endorsement from the independent Data Safety Monitoring Board for the FUNCTION-DMD trial may also influence investor confidence and market perception of Precision BioSciences.

What's Next

The company is set to host a live webcast on November 9, 2026, to present the late-breaking AASLD Phase 1 data, which will provide further insights into the PBGENE-HBV program. The filing does not specify any additional upcoming filings or votes.